According to Custom Market Insights (CMI), The Global Active Pharmaceutical Ingredients Market Size was valued at USD 211.23 billion in 2021 and is estimated to reach USD 355.87 billion by the end of 2030 at a CAGR of approximately 6% during the forecast period 2022-2030.d to grow at a compound annual growth rate of 6% during the forecast period from the year 2022- 2030.
Browse the full “Active Pharmaceutical Ingredients Market Size, Trends and Insights By Synthesis (Synthetic, Biotech), By Manufacturer (Captive, Merchant), By Type (Innovative, Generic), By Application (Oncology, Cardiovascular diseases, Ophthalmology, Orthopedic, Central nervous system and neurology, Gastroenterology, Nephrology, Others), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2023–2032” report at https://www.custommarketinsights.com/report/active-pharmaceutical/
Market Dynamics
Drivers
The demand for pharmaceutical drugs is robust and will continue to grow during the forecast period. As many people across the globe are leading a sudden Terry lifestyle due to urbanization and industrialization, the drug market will continue to grow. There is an increase in the demand for therapeutic drugs across the world. The Indian sector meets 50% of the demand for various vaccines from around the globe.
The pharmaceutical industry in China will also grow like in India in the coming years. As the number of chronic and infectious diseases continues to grow, the drug market will also increase. Research and development activities have been instrumental in providing innovative drugs. Biosimilars and biologics have great demand in the market. The statistics have shown that about 1.3 million people die as they have cancer. That has been 17.9 million deaths due to the increase in cardiovascular diseases. All of these will drive market growth in the coming years.
Restraints
The fluctuations in the pricing policy of various drugs will hamper the market’s growth in the coming years. The manufacturing nations may undergo many unanticipated changes, due to which the market growth will be hindered. Many developed nations across the globe depend on China to acquire the active ingredients which are outsourced to this country for production. The market will be hampered when the policy related to the pricing changes in China. Some manufacturing units may also hike their prices due to their monopoly in the market, and all of these will restrain the market’s growth in the coming year.
Opportunities
Pharmaceutical companies use small molecules to adopt newly developed treatment systems. This has been possible due to the highly potent active pharmaceutical ingredients. It will lead to the manufacturing of effective medicines in the coming years. Due to their increased efficiency, these medicines will be required in lower doses than the previous medicines. This is expected to be a major opportunity in the market’s growth. These highly potent active ingredients will continue to affect the market positively.
Challenges
The manufacturing of active pharmaceutical ingredients is costly, which is a major challenge in the market’s growth. The manufacturers of active pharmaceutical ingredients have to make large investments in the production plants to comply with the standards laid down by the government. This is another challenge that hampers the growth of the market. Acquiring clearance from these regulatory bodies is also expensive, and all of these factors will be major challenges to the market’s growth.
Report Highlights
The capital segment will have the largest market share. The market will grow as the raw materials are easily available and quickly delivered. Increasing the number of investments made by the manufacturers to improve their production capacities will also help the market’s growth in the coming years. The segment will have rapid growth in the coming years.
The innovative active pharmaceutical ingredients will have a larger market share as they have helped provide novel drug therapies. Research and development activities and the favorable laws of government will be some of the reasons that will drive the market growth of the segment.
Based on synthesis, the synthetic segment is expected to have a dominant position in the market. The segment has acquired a large market share in terms of revenue. As synthesizing the molecules is easy, this segment will grow well in the coming years. The raw materials used in manufacturing synthetic active pharmaceutical ingredients are also easily available, which is another reason that will lead to the market’s growth in the coming years.
The drugs with active pharmaceutical ingredients will be used more to treat various cardiovascular disorders. An increase in the geriatric population and an increase in chronic disorders will drive market growth in the coming years. The cardiology segment will have the largest market share in the coming years. These drugs will also be used on a large scale for treating cancer patients. Its application for treating neurological, pulmonary, and orthopedic disorders will drive market growth in the coming years.
Regional Snapshots
The North American region is expected to dominate the market in the coming years. This market was valued at 76.77 billion in recent years and will continue to dominate in the anticipated period. The market will continue to grow as there has been an increase in the prevalence of chronic disorders.
The government initiatives these regions to provide innovative drugs in the Active Pharmaceutical Ingredients market. The demand for biological drugs has also increased for treating chronic disorders. Research and development have been instrumental in providing biological active pharmaceutical ingredients in recent years. Increased Alzheimer’s disease and dementia cases will drive the market growth of the North American region during the forecast period.
The European region will also grow well in the coming years, though the government has increased the number of investments made for research purposes. The industry of biopharmaceuticals and pharmaceuticals has grown in the European region in recent years.
At the rate at which the Asia Pacific Active Pharmaceutical Ingredients market will grow, it will be able to outpace the North American and European markets during the forecast period. In the countries like India and China, there are a large number of manufacturing units present. Many countries from around the globe seek these nations as attractive destinations to outsource the production of active ingredients for these organizations. The policies laid down by the government in the Asia Pacific region support the market, which the market will continue to grow in the coming years.
Report Scope
| Feature of the Report | Details |
| Market Size in 2021 | USD 174.18 billion |
| Projected Market Size in 2030 | USD 355.87 billion |
| CAGR Growth Rate | 6.80% CAGR (2022-2030) |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Prominent Players | Merck & Co Inc., Teva Pharmaceutical Industries Ltd., Albemarle Corporation, Viatris Inc., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Cipla Inc., Dr. Reddy’s Laboratories Ltd., and Others |
| Key Segment | By Synthesis, Manufacture, Type, Application, and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Key Players
- Merck & Co Inc.
- Teva Pharmaceutical Industries Ltd.
- Albemarle Corporation
- Viatris Inc.
- Aurobindo Pharma
- Sun Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Cipla Inc.
- Dr. Reddy’s Laboratories Ltd.
Recent Developments
- The majority stake was acquired by Wavelength in the Vanamali Organics in the year 2021, and this acquisition will help strengthen the supply chain of Wavelength Pharmaceuticals in India.
Segments covered in the report
By Synthesis
- Synthetic
- Biotech
By Manufacturer
- Captive
- Merchant
By Type
- Innovative
- Generic
By Application
- Oncology
- Cardiovascular diseases
- Ophthalmology
- Orthopedic
- Central nervous system and neurology
- Gastroenterology
- Nephrology
- Others
On the basis of Geography
North America
- The U.S.
- Canada
- Mexico
Europe
- France
- The UK
- Spain
- Germany
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America